Key result
Prior cisplatin use linked to ~342% higher cisplatin-induced nephrotoxicity risk alongside hypoalbuminemia and frequent dosing.
Why the study?
What are the risk factors for cisplatin-induced nephrotoxicity in patients with gynecological cancer?
Observational (n=112)
No
What are the risk factors for cisplatin-induced nephrotoxicity in patients with gynecological cancer?
Odds Ratio: 4.42
Hydration without magnesium, history of cisplatin use, frequency of administration, and hypoalbuminemia are significant risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.
May guide monitoring in high-risk gynecological cancer patients; hypothesis-generating and requires prospective validation before practice change.
AIM: Risk factors for cisplatin-induced nephrotoxicity (CIN) vary by population. This study aimed to assess risk factors for CIN in patients with gynecological cancer. METHODS: Patients who underwent cisplatin-based chemotherapy for gynecological cancer between January 2009 and December 2015 at Aichi Medical University School of Medicine were included in this study. CIN was defined according to the 'risk, injury, failure, loss, and end-stage kidney disease' (RIFLE) criteria and classified as either risk (Class R) or injury (Class I). Analyses were performed using univariate and multivariate logistic regression models. RESULTS: Among 112 patients enrolled, 30 had CIN. Multivariate analysis revealed that hydration with magnesium (odds ratio [OR], 0.223), history of cisplatin use (OR, 4.420), and hypoalbuminemia (OR, 4.170) were risk factors for Class R, and that frequency of cisplatin administration (OR, 5.620) and hydration with magnesium (OR, 0.216) were risk factors for Class I. CONCLUSION: This study confirmed that hydration without magnesium, history of cisplatin use, frequency of cisplatin administration, and hypoalbuminemia are significant risk factors for CIN.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2017) conducted an observational in Gynecological cancer (n=112). Risk factors (history of cisplatin use, hypoalbuminemia, frequency of administration, lack of magnesium hydration) vs. Absence of risk factors was evaluated on Cisplatin-induced nephrotoxicity (CIN) according to RIFLE criteria (OR 4.420). History of cisplatin use (OR 4.420), hypoalbuminemia (OR 4.170), and frequency of administration (OR 5.620) were significant risk factors for cisplatin-induced nephrotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: